Multiple Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Landscape, Treatment Outlook, Key Companies

April 13 23:49 2023
Multiple Sclerosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Landscape, Treatment Outlook, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 100+ key pharma and biotech companies are working on 100+ pipeline drugs in the Multiple Sclerosis therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

The dynamics of the Multiple Sclerosis (MS) markets are anticipated to change in the coming years owing to the increasing prevalence of the disease, the launch of novel pipeline therapies, and increasing awareness.

“Multiple Sclerosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Multiple Sclerosis Market. 

The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Multiple Sclerosis Pipeline Analysis

Multiple Sclerosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Multiple Sclerosis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Multiple Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Mechanisms of Action of the Emerging Pipeline Therapies Include:

  • Dihydroorotate dehydrogenase inhibitor

  • Agammaglobulinaemia tyrosine kinase inhibitor

  • CD40 ligand inhibitor

  • Endothelial PAS domain-containing protein 1 inhibitor

  • B-cell activating factor inhibitor

  • Toll-like receptor 4 antagonists

  • CD4-positive T lymphocyte stimulant

  • Immunologic cytotoxicity

  • Cell replacements

  • Immunomodulator

  • ENO1 protein inhibitor

  • Bacteria replacements

Learn How the Ongoing Clinical & Commercial Activities will Affect the Multiple Sclerosis Therapeutic Segment @

Multiple Sclerosis Therapeutics Landscape

There are approx. 100+ key companies developing therapies for Multiple sclerosis. Currently, TG Therapeutics is leading the therapeutic market with its Multiple sclerosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Multiple Sclerosis Therapeutics Market, Include:

AB Science, ABION, Alkermes, ANOKION, Antisense Therapeutics, Apimeds Inc., ASLAN Pharmaceuticals, AstraZeneca, Atara Biotherapeutics, Autobahn Therapeutics, Bayer HealthCare, Biocad, Biogen, BrainStorm Cell Limited, Bristol-Myers Squibb, CinnaGen, Clene Nanomedicine, CytoDyn, Emerald Health Pharmaceuticals, f5 Therapeutics, Genentech, GeNeuro SA, GlaxoSmithKline, Gossamer Bio, Hanmi Pharmaceutical, HuniLife Biotechnology, Inc., Immune Response BioPharma, Inc., ImStem Biotechnology, Lucid Psycheceuticals, Mapi Pharma, Merck Healthcare KGaA, Merck Serono, Novartis, Pear Therapeutics, Pipeline Therapeutics, RedHill Biopharma, RemeGen Co., Ltd., Sanofi, Sarepta Therapeutics, TG Therapeutics, Inc., Voronoi, ZyVersa Therapeutics, and many others.

Multiple Sclerosis Emerging and Marketed Drugs Covered in the Report Include:

  • ALKS 8700: Alkermes/Biogen

  • ANK-700: ANOKION

  • Arbaclofen (Arbaclofen ER): Osmotica Pharmaceutical

  • ATA188: Atara Biotherapeutics

  • BMS-986196: Bristol Myers Squibb

  • CNM-Au8: Clene Nanomedicine

  • Evobrutinib/M2951: Merck Healthcare KGaA

  • Fenebrutinib: Hoffman-La-Roche

  • GB7208: Gossamer Bio

  • IMCY-0141: ImCyse

  • IMS-001: ImStem Biotechnology

  • IMU-838: Immunic

  • NeuroVax: Immune Response BioPharma, Inc.

  • Pear-006: Pear therapeutics

  • RC18: RemeGen

  • Temelimab: GeNeuro

  • Tolebrutinib (SAR442168): Sanofi

  • Ublituximab: TG Therapeutics, Inc.

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Multiple Sclerosis Current Treatment Patterns

4. Multiple Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple Sclerosis Late Stage Products (Phase-III)

7. Multiple Sclerosis Mid-Stage Products (Phase-II)

8. Multiple Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple Sclerosis Discontinued Products

13. Multiple Sclerosis Product Profiles

14. Key Companies in the Multiple Sclerosis Market

15. Key Products in the Multiple Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Multiple Sclerosis Unmet Needs

18. Multiple Sclerosis Future Perspectives

19. Multiple Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States